198 related articles for article (PubMed ID: 32864984)
21. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
22. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
Clark NP
Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological effects and clinical applications of ultra low molecular weight heparins.
Liu Z; Ji S; Sheng J; Wang F
Drug Discov Ther; 2014 Feb; 8(1):1-10. PubMed ID: 24647152
[TBL] [Abstract][Full Text] [Related]
24. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis.
Dong Y; Wang Y; Ma RL; Liu M; Gao JZ; Su WY; Yan L; Sun JJ
J Thromb Thrombolysis; 2019 Oct; 48(3):400-412. PubMed ID: 31062143
[TBL] [Abstract][Full Text] [Related]
26. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
[TBL] [Abstract][Full Text] [Related]
27. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
28. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events.
Ko RH; Michieli C; Lira JL; Young G
Thromb Res; 2014 Sep; 134(3):643-7. PubMed ID: 25087891
[TBL] [Abstract][Full Text] [Related]
29. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
30. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
31. PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count.
Scamuffa MC; Morano SG; Serrao A; Bruzzese A; Stocchi F; Santoro C; Vozella F; Latagliata R; Chistolini A
J Thromb Thrombolysis; 2020 Apr; 49(3):426-430. PubMed ID: 31981040
[TBL] [Abstract][Full Text] [Related]
32. Factor Xa inhibitors for acute coronary syndromes.
Brito V; Ciapponi A; Kwong J
Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
[TBL] [Abstract][Full Text] [Related]
33. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.
Samama MM
Drugs Aging; 2011 Mar; 28(3):177-93. PubMed ID: 21329400
[TBL] [Abstract][Full Text] [Related]
34. Risks and benefits of low molecular-weight heparin and target-specific oral anticoagulant use for thromboprophylaxis in medically ill patients.
Hale G; Brenner M
Am J Cardiovasc Drugs; 2015 Oct; 15(5):311-22. PubMed ID: 25957095
[TBL] [Abstract][Full Text] [Related]
35. Clinical experiences with low-molecular weight heparins in pediatric patients.
Hofmann S; Knoefler R; Lorenz N; Siegert G; Wendisch J; Mueller D; Taut-Sack H; Dinger J; Kabus M
Thromb Res; 2001 Sep; 103(5):345-53. PubMed ID: 11553367
[TBL] [Abstract][Full Text] [Related]
36. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
37. A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience.
Warad D; Rao AN; Mullikin T; Graner K; Shaughnessy WJ; Pruthi RK; Rodriguez V
Thromb Res; 2015 Aug; 136(2):229-33. PubMed ID: 26026634
[TBL] [Abstract][Full Text] [Related]
38. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
[TBL] [Abstract][Full Text] [Related]
40. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
Raskob GE; Hirsh J
Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
